Gergely Tóth

Dr Gergely Tóth founded Gardedam Therapeutics in Palo Alto, CA in 2009 and is CEO of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the School of Pharmacy at University College London (UK) as a Honorary Lecturer and with the Research Center for Natural Sciences at the Hungarian Academy of Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a serial entrepreneur with a long-term focus on developing therapeutics for neurodegenerative diseases.

He holds a Ph.D. from the Department of Biomedical Sciences at Creighton University (U.S.) in 2001, and an Executive M.B.A. in 2012 from the Judge Business School at the University of Cambridge (UK). He was a post-doctoral fellow at the Department of Molecular Biology at the University of California at Berkeley (U.S.). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he mostly pursued drug discovery research for Parkinson’s disease and Alzheimer’s disease.